title: [Pulmonary arterial hypertension. Therapy with the endothelin-1 receptor antagonist bosentan].
abstract: Activation of the endothelin-1 system plays a key role in the pathogenesis of pulmonary arterial hypertension (PAH). The endothelin-1 receptor antagonist bosentan inhibits the action of endothelin-1 at both receptor subtypes (ET(A) and ET(B) receptors) and has been approved for PAH therapy since 2001. Recent data were presented at an international symposium in Barcelona in February 2006.
authors.affiliation: Redaktion Medizinische Monatsschrift für Pharmazeuten, Birkenwaldstr. 44, 70191 Stuttgart. amusch@deutscher-apothekerverlag.de
authors.forename: Annemarie
authors.initials: A
authors.lastname: Musch
mesh_terms: D000959:Antihypertensive Agents / Q000627:therapeutic use*; D000077300:Bosentan; D065128:Endothelin Receptor Antagonists; D006333:Heart Failure / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D006976:Hypertension, Pulmonary / Q000150:complications / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D012595:Scleroderma, Systemic / Q000209:etiology / Q000517:prevention & control; D013449:Sulfonamides / Q000627:therapeutic use*
chemical_list: D000959:Antihypertensive Agents; D065128:Endothelin Receptor Antagonists; D013449:Sulfonamides; D000077300:Bosentan